RNA Sequencing for Detecting Functional Gene Fusions

You are reading version 1 of this direction, frozen 2026-10-04. The latest version is version 2.

Version 1 of 219 papers26 conceptsfrozen 2026-10-04

In the search for the drivers of cancer, genomic structural variations—where chromosomes break and reattach in new configurations—are among the most potent triggers. When these breaks join two previously independent genes, they create a "gene fusion" that can produce a chimeric, oncogenic protein.

While DNA sequencing is the traditional tool for finding these breaks, a growing body of research suggests that the transcriptome, rather than the genome, provides the most accurate map of which fusions actually drive disease.

The Intron Problem

The primary challenge in identifying gene fusions at the DNA level is the sheer scale and complexity of the human genome. Genes are separated by vast stretches of non-coding DNA called introns. As C. Xu and colleagues note in their Expert Consensus on NRG1/2 Gene Fusions, certain genes have "expansive intronic regions" where standard DNA-based sequencing probes often fail to provide adequate coverage.

RNA sequencing (RNA-seq) bypasses this "dark matter" of the genome. Because the cell’s natural splicing machinery removes introns to create a mature mRNA transcript, the fusion junction—the point where two genes meet—is brought into clear focus. By analyzing the spliced product, researchers like Nike Beaubier have shown that whole-transcriptome sequencing can identify functional rearrangements that DNA-only approaches might miss (Clinical validation of the Tempus xO assay).

Distinguishing Drivers from Noise

Not every break in the DNA results in a functional protein. A genomic rearrangement might occur in a non-coding region, or it might join two genes in a way that disrupts the "reading frame," resulting in a non-functional transcript.

RNA-seq acts as a filter for biological relevance. As Misako Nagasaka explains in a pan-tumor survey of ROS1 fusions, highly sensitive RNA testing is required to confirm the presence of in-frame transcripts. These are the only transcripts capable of producing the oncogenic proteins that drive tumor progression.

This "transcriptomic ground truth" was vividly demonstrated in a case report by Qing Yi and team: while DNA sequencing identified a rare, ambiguous intergenic fusion, RNA sequencing revealed a canonical, actionable ROS1 fusion, allowing the patient to receive life-saving targeted therapy.

Reconstructing the Chimeric Protein

To understand why a fusion works, researchers must look at the structure of the resulting protein. Tools like Pegasus, developed by Francesco Abate and others, reconstruct full chimeric sequences from RNA-seq data. This allows for a precise evaluation of whether the fusion retains critical functional domains, such as kinase domains, which are often the targets of modern drugs.

Similarly, the FuGePrior algorithm prioritizes candidates by checking for "structural integrity," such as the preservation of promoter regions. This helps distinguish "driver" mutations from "passenger" events—random genomic noise that occurs as a tumor becomes unstable but does not contribute to its growth.

Beyond Simple Pairs: Complex Rearrangements

The move toward RNA-based discovery has also revealed that gene fusions are more complex than simple A-to-B joins. Claudia Calabrese and colleagues identified a novel class of "bridged" gene fusions, where a third, distal genomic fragment acts as a connector between two genes. These complex events are nearly impossible to interpret using DNA sequencing alone but become visible when the final, fused RNA transcript is sequenced.

Furthermore, the impact of these fusions extends beyond cancer. Research by Yogindra Raghav has identified gene fusions associated with Amyotrophic Lateral Sclerosis (ALS), suggesting that transcriptomic instability is a broader hallmark of disease than previously realized.

The Future: Long-Reads and Multi-Omics

While short-read RNA-seq is the current standard, it can struggle with repetitive regions or very long transcripts. Taobo Hu and colleagues have demonstrated that Third-Generation (long-read) Sequencing can navigate these "hotspots" of structural variation more effectively.

By integrating these long-read transcriptomic insights with genomic data, researchers can finally bridge the gap between a "broken" piece of DNA and the functional chimeric protein that drives a cell toward malignancy. As David Jones and the team studying medulloblastoma concluded, this integrative approach is the key to unlocking new doors for targeted therapies.

Papers in this version

History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 20 papers
  2. Version 1 · 2026-10-04 · 19 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_transcriptome_based_fusion_detection_640a4b11,
  title = {transcriptome-based fusion detection},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/transcriptome-based-fusion-detection/rdr_640a4b11388546ec82b4f7e4ec3510a4},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}

This exact version (version 1, frozen text):

@misc{lacuna_rna_sequencing_for_detecting_functional__640a4b11_v1,
  title = {RNA Sequencing for Detecting Functional Gene Fusions},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/rna-sequencing-for-detecting-functional-gene-fusions/rdr_640a4b11388546ec82b4f7e4ec3510a4/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}